Bibliografía
1. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis. 2012 Jul;55 Suppl 1:S33-42.
2. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014 Aug;312(6):631–40.
3. Perez Cachafeiro S, Del Amo J, Iribarren JA, Salavert Lleti M, Gutierrez F, Moreno A, et al. Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. Clin Infect Dis. 2009 May;48(10):1467–70.
4. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001 Aug;33(4):562–9.
5. Berenguer J, Rodriguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, et al. Eradication of HCV and non-liver-related non-AIDS-related events in HIV/HCV coinfection. Hepatology. 2017 Jan;
6. Barreiro P, Labarga P, Martin-Carbonero L, Amor A, Ruiz-Sancho A, Castellares C, et al. Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. Vol. 11, Antiviral therapy. England; 2006.
7. Hadigan C, Kottilil S. Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. Vol. 306, JAMA. United States; 2011 Jul.
8. Kim AI, Dorn A, Bouajram R, Saab S. The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis. Vol. 8, HIV medicine. England; 2007 Jul.
9. Milazzo L, Lai A, Calvi E, Ronzi P, Micheli V, Binda F, et al. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med. 2017 Apr;18(4):284–91.
10. Menard A, Colson P, Catherine D, Isabelle R, Christelle T, Meddeb L, et al. First Real Life Evidence of New Direct-acting Antivirals (DAA) in Co-infected HIV HCV Patients: Better than Ever. Vol. 62, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. United States; 2016. p. 947–9.
11. Kwo P, Gane EJ, Peng C-Y, Pearlman B, Vierling JM, Serfaty L, et al. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. Gastroenterology. 2017 Jan;152(1):164–175.e4.
12. Laufer NL, Rockstroh JK. Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV. Vol. 12, Expert review of anti-infective therapy. England; 2014 Feb.
13. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. Vol. 373, The New England journal of medicine. United States; 2015 Aug.
14. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. Vol. 373, The New England journal of medicine. United States; 2015 Aug.
15. Montoya-Ferrer A, Fierer DS, Alvarez-Alvarez B, de Gorgolas M, Fernandez-Guerrero ML. Acute hepatitis C outbreak among HIV-infected men, Madrid, Spain. Vol. 17, Emerging infectious diseases. United States; 2011. p. 1560–2.
16. Berenguer J, Rivero A, Jarrin I, Nunez MJ, Vivancos MJ, Crespo M, et al. Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. Open forum Infect Dis. 2016 Mar;3(2):ofw059.
17. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008 Jan;48(1):148–62.
18. Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, et al. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat. 2017 Jan;24(1):22–7.
19. Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, et al. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology. 2016 Feb;150(2):419–29.
1. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis. 2012 Jul;55 Suppl 1:S33-42.
2. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014 Aug;312(6):631–40.
3. Perez Cachafeiro S, Del Amo J, Iribarren JA, Salavert Lleti M, Gutierrez F, Moreno A, et al. Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. Clin Infect Dis. 2009 May;48(10):1467–70.
4. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001 Aug;33(4):562–9.
5. Berenguer J, Rodriguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, et al. Eradication of HCV and non-liver-related non-AIDS-related events in HIV/HCV coinfection. Hepatology. 2017 Jan;
6. Barreiro P, Labarga P, Martin-Carbonero L, Amor A, Ruiz-Sancho A, Castellares C, et al. Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. Vol. 11, Antiviral therapy. England; 2006.
7. Hadigan C, Kottilil S. Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. Vol. 306, JAMA. United States; 2011 Jul.
8. Kim AI, Dorn A, Bouajram R, Saab S. The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis. Vol. 8, HIV medicine. England; 2007 Jul.
9. Milazzo L, Lai A, Calvi E, Ronzi P, Micheli V, Binda F, et al. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med. 2017 Apr;18(4):284–91.
10. Menard A, Colson P, Catherine D, Isabelle R, Christelle T, Meddeb L, et al. First Real Life Evidence of New Direct-acting Antivirals (DAA) in Co-infected HIV HCV Patients: Better than Ever. Vol. 62, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. United States; 2016. p. 947–9.
11. Kwo P, Gane EJ, Peng C-Y, Pearlman B, Vierling JM, Serfaty L, et al. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. Gastroenterology. 2017 Jan;152(1):164–175.e4.
12. Laufer NL, Rockstroh JK. Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV. Vol. 12, Expert review of anti-infective therapy. England; 2014 Feb.
13. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. Vol. 373, The New England journal of medicine. United States; 2015 Aug.
14. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. Vol. 373, The New England journal of medicine. United States; 2015 Aug.
15. Montoya-Ferrer A, Fierer DS, Alvarez-Alvarez B, de Gorgolas M, Fernandez-Guerrero ML. Acute hepatitis C outbreak among HIV-infected men, Madrid, Spain. Vol. 17, Emerging infectious diseases. United States; 2011. p. 1560–2.
16. Berenguer J, Rivero A, Jarrin I, Nunez MJ, Vivancos MJ, Crespo M, et al. Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. Open forum Infect Dis. 2016 Mar;3(2):ofw059.
17. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008 Jan;48(1):148–62.
18. Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, et al. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat. 2017 Jan;24(1):22–7.
19. Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, et al. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology. 2016 Feb;150(2):419–29.